WX-0593 combined with an epithelial growth factor receptor (EGFR) monoclonal antibody in the treatment of xenograft tumors carrying triple EGFR mutations

BACKGROUND: To evaluate the safety and therapeutic efficacy of WX-0593, a newly developed potent anaplastic lymphoma kinase (ALK) inhibitor, in combination with an epithelial growth factor receptor (EGFR) monoclonal antibody (QL1203 or Vectibix) for the treatment of xenograft tumors carrying mutant...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Qingmei, Chen, Dongmei, Wang, Xinmei, Yang, Yingying, Zhao, Shuyong, Dong, Xin, Ma, Cuicui, Zhang, Xin, Duan, Huicheng, Sun, Yan, Zheng, Shansong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279820/
https://www.ncbi.nlm.nih.gov/pubmed/35845484
http://dx.doi.org/10.21037/atm-22-2780

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279820/
https://www.ncbi.nlm.nih.gov/pubmed/35845484
http://dx.doi.org/10.21037/atm-22-2780

Ejemplares similares